MS · State regulatory reference

Mississippi.

Restrictive

Mississippi has a documented, dual-board restriction on compounded GLP-1s backed by primary sources. The State Board of Medical Licensure's Rule 1.5(F) prohibits off-label use of a non-FDA-approved legend drug solely for weight loss; in its Guidance Regarding Semaglutide-Based Medications (August 2023), the Board rescinded its prior off-label waiver and rejected a waiver for compounded semaglutide. A July 2024 Board Order (Supplemental Guidance on GLP-1 and GIP Medications) then created a narrow exemption allowing compounded GLP-1/GIP only for a documented specific clinical need or FDA shortage plus verified API sourcing. The Board of Pharmacy separately warns that compounding semaglutide salt forms fails FDA bulk-substance requirements and 'may result in enforcement action.'

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Mississippi Medical Board

https://www.msbml.ms.gov/ ↗

Pharmacy board

Mississippi Board of Pharmacy

https://www.mbp.ms.gov/ ↗

TPC notes

Telehealth

The Board of Medical Licensure's telemedicine rule (Part 2635, Ch. 5, under Miss. Code § 73-25-34) permits establishing a valid physician-patient relationship via telemedicine without a prior in-person visit if the technology supports an equivalent exam; a questionnaire alone is not sufficient.

Compounding

Both the Board of Pharmacy and Board of Medical Licensure treat compounded semaglutide/GLP-1 salt forms as failing FDA bulk-substance requirements; compounded GLP-1/GIP is permitted only under the 2024 conditional exemption (specific clinical need or FDA shortage, plus COA/API verification of the source).

Sources